Matthew B. Murphy
CIK: 0001865778
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Nautilus Biotechnology, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Mar 2, 2026NAUT
Nautilus Biotechnology, Inc.
Award(A)DirectStock Option (Right to Buy)
160K shares- - Sep 4, 2025NAUT
Nautilus Biotechnology, Inc.
Purchase(P)Indirect20K shares at avg. $0.64$13K - Mar 3, 2025NAUT
Nautilus Biotechnology, Inc.
Award(A)DirectStock Option (Right to Buy)
160K shares-
1-3 of 3 transactions
About Murphy Matthew B.
Murphy Matthew B. (SEC CIK 0001865778) files insider reports with the SEC as General Counsel of Nautilus Biotechnology, Inc. (NAUT).
Signal8 holds 3 ownership filings by Murphy Matthew B., all Form 4s, filed between Mar 4, 2025 and Mar 4, 2026. Those filings report 3 transactions, from Mar 3, 2025 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Murphy Matthew B.'s filings is in SEATTLE, WA.
Recent filings by Murphy Matthew B.
Other insiders filing for Nautilus Biotechnology, Inc. (NAUT)
- Posard Matthew L., Director
- NAZEM FARZAD, Director
- Akinsanya Karen, Director
- McIlwain Matthew S, Director
- Epperly Melissa B,, Director
- AH Equity Partners Bio II, L.L.C., 10% Owner